The Australian medical landscape is abuzz with the emergence of retatrutide, a novel dual GIP and GLP-1 receptor agonist showing significant results in clinical trials for addressing obesity. This https://tealbookmarks.com/story21742289/the-new-retatrutide-australia-a-potential-prospect-for-weight-management